SNNA News and Press, Sienna Biopharmaceuticals Inc. From 02/08/19

CORAL GABLES, FL / ACCESSWIRE / February 8, 2019 / The tech stock market will continue to be successful if, and only if, companies in the sector continue to invest in ideas that can be used to design innovative technologies and services that will appeal to consumers. As we've seen in recen...

Thinly traded nano cap Sienna Biopharmaceuticals ( SNNA +21.5% ) is up almost a 14x surge in volume in early trade in reaction to positive data from a pivotal study evaluating SNA-001 as a topical pretreatment to standard laser hair removal. More news on: Sienna Biopharmaceuticals, H...

-- SNA-001 addresses a large unmet need in laser hair removal by treating light hair using a topical solution of silver photoparticles, an ultra-efficient light absorber -- -- If cleared, SNA-001 has potential to expand the $3 billion U.S. laser hair removal market as an effective ...

-- 27% of subjects achieved 75% reduction in PASI score (PASI 75) vs 13% with vehicle; 29% of subjects achieved two-grade improvement on IGA and ‘clear’ or ‘almost clear’ skin vs 13% with vehicle (statistically significant) -- Subjects achieved 58% improveme...

Stocks in News: ESPR Esperion announces positive results from phase 3 bempedoic acid/ezetimibe combination pill study Discussion: Positive top-line results from the pivotal Phase 3 trial of Esperion’s ( ESPR ) bempedoic acid/ezetimibe combination pill study ( 1...

Sienna Biopharmaceuticals ( SNNA +2.6% )  announces results from a first-in-human study of JAK3/TrkA inhibitor SNA-125 for the topical treatment of mild-to-moderate psoriasis. More news on: Sienna Biopharmaceuticals, Healthcare stocks news, Stocks on the move, Read more .....

-- Phase 1/2 study data of SNA-125 in atopic dermatitis on track to be released in fourth quarter of 2018 -- SNA-125 Phase 2 studies expected to begin in second half of 2019 WESTLAKE VILLAGE, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA...